Chardan Capital Trims Notable Labs (NASDAQ:NTBL) Target Price to $7.00

Notable Labs (NASDAQ:NTBL) had its target price trimmed by Chardan Capital from $9.00 to $7.00 in a report published on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, JMP Securities lowered their price objective on Notable Labs from $13.00 to $9.00 and set a market outperform rating on the stock in a research note on Tuesday, December 19th.

Notable Labs Stock Down 2.5 %

Notable Labs stock opened at $0.96 on Monday. The firm has a 50 day moving average price of $1.44. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.65 and a current ratio of 5.65. The firm has a market cap of $2.13 million, a PE ratio of -0.26 and a beta of 0.77. Notable Labs has a 12 month low of $0.83 and a 12 month high of $11.20.

Institutional Investors Weigh In On Notable Labs

A hedge fund recently bought a new stake in Notable Labs stock. Industry Ventures L.L.C. acquired a new stake in Notable Labs, Ltd. (NASDAQ:NTBL) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 204,424 shares of the company’s stock, valued at approximately $386,000. Notable Labs accounts for approximately 0.6% of Industry Ventures L.L.C.’s investment portfolio, making the stock its 6th largest holding. Industry Ventures L.L.C. owned approximately 9.21% of Notable Labs as of its most recent filing with the SEC. Institutional investors own 70.48% of the company’s stock.

About Notable Labs

Notable Labs, Ltd., a clinical-stage platform therapeutics company, engages in developing predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient is likely to respond to that specific therapeutic.